{"Symbol": "EGRX", "AssetType": "Common Stock", "Name": "Eagle Pharmaceuticals, Inc", "Description": "Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Drug ManufacturersSpecialty & Generic", "Address": "50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677", "FullTimeEmployees": "108", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "538565056", "EBITDA": "11699000", "PERatio": "257.7222", "PEGRatio": "0.91", "BookValue": "13.523", "DividendPerShare": "None", "DividendYield": "0", "EPS": "0.177", "RevenuePerShareTTM": "12.983", "ProfitMargin": "-0.0254", "OperatingMarginTTM": "0.046", "ReturnOnAssetsTTM": "0.0197", "ReturnOnEquityTTM": "-0.0253", "RevenueTTM": "177363008", "GrossProfitTTM": "134995000", "DilutedEPSTTM": "-0.337", "QuarterlyEarningsGrowthYOY": "-0.919", "QuarterlyRevenueGrowthYOY": "-0.26", "AnalystTargetPrice": "49.33", "TrailingPE": "257.7222", "ForwardPE": "13.0548", "PriceToSalesRatioTTM": "3.1186", "PriceToBookRatio": "2.9468", "EVToRevenue": "2.655", "EVToEBITDA": "43.4367", "Beta": "0.9462", "52WeekHigh": "64.94", "52WeekLow": "33.8", "50DayMovingAverage": "45.8778", "200DayMovingAverage": "47.409", "SharesOutstanding": "13607000", "SharesFloat": "11021238", "SharesShort": "1999018", "SharesShortPriorMonth": "1840487", "ShortRatio": "12.94", "ShortPercentOutstanding": "0.14", "ShortPercentFloat": "0.2304", "PercentInsiders": "12.666", "PercentInstitutions": "94.138", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}